Results 121 to 130 of about 59,165 (246)

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

open access: yesArthritis &Rheumatology, EarlyView.
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman   +6 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

open access: yesArthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli   +4 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

The absent presence of disability in British higher education

open access: yesBritish Educational Research Journal, EarlyView.
Abstract Rates of disability disclosure are steadily increasing in British higher education (HE), with 18% of the student population having a known disability in 2023/24. It might be assumed that progress is being made with increased representation, rights and support for disabled students.
G. Koutsouris   +5 more
wiley   +1 more source

Waitlist mortality of young patients with biliary atresia: Impact of allocation policy and living donor liver transplantation

open access: yesLiver Transplantation, EarlyView., 2022
Abstract Patients with biliary atresia (BA) below 2 years of age in need of a transplantation largely rely on partial grafts from deceased donors (deceased donor liver transplantation [DDLT]) or living donors (living donor liver transplantation [LDLT]).
Hedayatullah Esmati   +10 more
wiley   +1 more source

Too Old to Bother: CEO Age and Corporate Stakeholder Engagement

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT We examine how CEO age, a key demographic attribute, affects corporate stakeholder engagement. Drawing on Upper Echelons Theory, we argue that older CEOs are less responsive to stakeholder concerns because of heightened conservatism, shorter time horizons, and greater risk aversion.
Mehwish Yousaf, Pascal Nguyen
wiley   +1 more source

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens   +10 more
wiley   +1 more source

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Emmanuel Chigutsa   +2 more
wiley   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen   +4 more
wiley   +1 more source

N‐terminal pro‐brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.
Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy